Aton Pharma Announces Distribution Partnership...( LAWRENCEVILLE N.J. May 12 /- Aton...)

LAWRENCEVILLE, N.J., May 12 /PRNewswire/ -- Aton Pharma, Inc., a global specialty pharmaceutical company, announced today that it has signed a distribution agreement with Meizler Biopharma S/A to commercialize CUPRIMINE(R) and SYPRINE(R) in Brazil. Cuprimine is currently approved in Brazil, and Meizler is working to obtain regulatory approval of Syprine.

"Cuprimine and Syprine are medically essential products, and Aton is committed to making these products available wherever they are needed," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "Brazil is the largest country in Latin America, and we are very pleased that we found Meizler to help us address the needs of patients in this country."

"Meizler has a long history of providing important medical therapies in Brazil," stated Avi Meizler, Meizler's President. "Cuprimine and Syprine both perfectly complement our current portfolio, and we look forward to helping Aton expand their presence in Brazil."

Meizler is a Brazilian Pharmaceutical company, headquartered in Sao Paulo, active in both the out-patient and hospital segments of the pharmaceutical industry. The company currently markets more than 40 products on the Brazilian market and has international partnerships in place with companies in the United States, Europe and Asia, to which Meizler provides various regulatory and commercial services. Using an advanced management and logistics system, Meizler is able to rapidly supply its high quality products to providers and patients. For more information, see http://www.meizler.com.br.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global specialty pharmaceutical company providing essential treatments for under- treated diseases and rare illnesses around the world. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access
'/>"/>